InStride Health, a provider of outpatient specialty treatment for pediatric anxiety and OCD, has successfully closed an oversubscribed $30M Series B funding round. Leading the investment is General Catalyst, with participation from existing investors .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation.
This significant funding round is poised to empower InStride Health to enhance clinical quality and extend its reach into new markets. The company remains dedicated to its mission of ensuring insurance-based access to top-tier mental health care services. With this latest injection of capital, InStride Health’s total funding stands at $56M, marking a significant milestone in its growth journey.
[Sign up here to never miss these candid conversations delivered straight to your inbox.]
